21Mar 2022
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes

In patients with type 2 diabetes (T2D), chronic kidney disease (CKD) is the most common cause of kidney failure. With its increasing prevalence and limited treatment options, CKD is a significant contributor to the global burden of disease. Although recent guidelines for control of hypertension and hyperglycemia, as well as the use of renin‐angiotensin system inhibitors and, more recently, sodium‐glucose co‐transporter‐2 inhibitors, have improved outcomes for patients with CKD and diabetes, there is still a high residual risk of CKD progression and adverse cardiovascular (CV) events. This review discusses the recently published FIDELIO‐DKD and FIGARO‐DKD studies and FIDELITY prespecified individual patient analysis. Together, these studies have established finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and CV protection and welcomed addition to the pillars of treatment to slow CKD progression in patients with T2D.

  • #endo-diabetology

Like

Save

Share